Clinical Trials Browser

Bile Duct Neoplasms, Cholangiocarcinoma

Limited Stage Small Cell Lung Cancer

Breast Neoplasms

Carcinoma, Hepatocellular, Cholangiocarcinoma

Carcinoma, Hepatocellular

Liver Neoplasms

Pancreatic Neoplasms

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Neoplasm Metastasis, Pancreatic Neoplasms, Endometrial Neoplasms

Hemangiosarcoma, Liposarcoma, Osteosarcoma

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Glioblastoma

Lung Neoplasms, Small Cell Lung Carcinoma

Gastric Adenocarcinoma

Non-Muscle Invasive Bladder Neoplasms

Cholangiocarcinoma

Carcinoma, Hepatocellular

Small Cell Lung Carcinoma

Carcinoma, Hepatocellular

Lung Neoplasms

Biliary Tract Neoplasms

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Carcinoma, Non-Small-Cell Lung

Lung Neoplasms, Small Cell Lung Carcinoma

Node; Prostate

Platinum-Resistant Lung Small Cell Carcinoma

Carcinoma, Non-Small-Cell Lung

Advanced Biliary Tract Carcinoma

Hepato Cellular Carcinoma

Clinical Trials

Y-90 With Durvalumab/Gem/Cis in Intrahepatic Cholangio

TIGOS-LS

DTP

Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer

Durvalumab and Tremelimumab After Radioembolization for the Treatment of Unresectable, Locally Advanced Liver Cancer

A Phase II Study of Single Tremelimumab With Regular Interval Durvalumab Plus Gemcitabine and Cisplatin in Locally Advanced Unresectable/Metastatic Combined Hepatocellular-cholangiocarcinoma

Gemcitabine, Nab-paclitaxel, Durvalumab, and Oleclumab Before Surgery for the Treatment of in Resectable/Borderline Resectable Primary Pancreatic Cancer

ADAPT-BLADDER

Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors

DOSa

Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial

STERIMGLI

Phase II Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer

Phase 2 Study of Trastuzumab Deruxtecan in the Neoadjuvant Treatment, or Trastuzumab Deruxtecan Plus Capecitabine Plus Durvalumab(MEDI4736) in the Preoperative and Postoperative Adjuvant Treatment for Patients With HER2 Positive Gastric and Gastroesophageal Junction Adenocarcinoma

ENHANCE

A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or Rearrangement

Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial

MOZART

Y-90 Radioembolization, Durvalumab, Tremelimumab, and Zanzalintinib for the Treatment of Unresectable and Locally-Advanced Hepatocellular Carcinoma

Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer

Emavusertib (CA-4948) in Combination With Cisplatin, Gemcitabine, and Durvalumab in Patients With Untreated Advanced or Metastatic Biliary Tract Cancer

358

Multimodality Treatment in Stage III Non-small Cell Lung Cancer (NSCLC)

Radiotherapy and Durvalumab/Durvalumab Combo (Tremelimumab/Olaparid) for Small Cell Lung Cancer

POSTCARD

Durvalumab and Lurbinectedin for the Treatment of Relapsed or Refractory Small Cell Lung Cancer

MINUTE

TRADE-hypo

TACTIC

IIT2025-03-YANG-LIFT-HCC